Capsaicin Cream for Nausea and Vomiting: Evidence Summary
Topical capsaicin cream (0.1%) is supported by guideline-level evidence specifically for cannabinoid hyperemesis syndrome (CHS), but evidence for other causes of nausea and vomiting remains limited to small trials showing potential benefit for delayed chemotherapy-induced nausea.
Primary Indication: Cannabinoid Hyperemesis Syndrome
The 2024 AGA Clinical Practice Update on CHS explicitly recommends topical capsaicin (0.1%) cream as part of the management strategy for acute and short-term care 1. The mechanism involves activation of transient receptor potential vanilloid type 1 (TRPV1) receptors, which may counteract the downregulation caused by chronic cannabinoid use.
Application Protocol for CHS:
- Concentration: 0.1% capsaicin cream
- Site: Apply to anterior abdomen
- Frequency: Four times daily
- Duration: Monitor closely for efficacy and adverse effects
- Expected response: Symptom improvement within 30-60 minutes in responders
Supporting Research Evidence:
A 2020 double-blind RCT (n=30) demonstrated that capsaicin reduced nausea severity at 60 minutes (mean 3.2 cm vs 6.4 cm on VAS, difference -3.2 cm) with 29.4% achieving complete nausea resolution versus 0% with placebo 2. However, a 2024 systematic review found mixed evidence across studies, with some observational studies failing to show significant benefit on ED length of stay 3.
Secondary Indication: Delayed Chemotherapy-Induced Nausea and Vomiting
A 2024 randomized controlled trial (n=150) provides the strongest evidence for capsaicin in delayed CINV, showing:
- Reduced nausea incidence: 36.0% vs 53.3% (p=0.033) during delayed phase (days 2-5)
- Reduced vomiting incidence: 28.0% vs 42.7% (p=0.060) during delayed phase
- No grade 3 nausea in capsaicin group vs 9.3% in placebo (p=0.007)
- Application: 2g of 0.075% capsaicin ointment four times daily to abdomen for 5 days 4
Important caveat: This is not included in current ASCO antiemetic guidelines 5, 6, which recommend standard regimens (NK1 antagonists, 5-HT3 antagonists, dexamethasone, olanzapine) as first-line therapy. Capsaicin should be considered adjunctive therapy only.
Limited Evidence for Other Indications
- Nausea and vomiting of pregnancy: One 2023 pilot RCT (n=30) showed a trend toward decreased treatment time (79.9 vs 97.3 minutes, p=0.1) but no significant difference in symptom scores 7
- General nausea/vomiting: No guideline support; palliative care guidelines 8 recommend dopamine antagonists, 5-HT3 antagonists, and other standard antiemetics without mentioning capsaicin
Critical Clinical Considerations
When NOT to Use:
- Wounds or damaged skin (FDA contraindication) 9
- Allergy to capsicum or chili peppers 9
- Not FDA-approved for nausea/vomiting - labeled only as external analgesic 9
Expected Adverse Effects:
- Burning sensation at application site (common, typically resolves with continued use)
- Approximately 3-6% discontinuation rate due to skin irritation 2
- Avoid eyes, lips, nose, mucous membranes 9
Practical Application:
- Apply thin film to abdomen
- Gently rub until absorbed
- Wash hands immediately after application
- Do not apply heat or tight bandages to treated area 9
Clinical Algorithm
For CHS patients in ED:
- Apply 0.1% capsaicin cream to abdomen as adjunct to standard antiemetics (dopamine antagonists, benzodiazepines)
- Reassess at 30 and 60 minutes
- If no improvement by 60 minutes, consider alternative therapies
For delayed CINV (days 2-5 post-chemotherapy):
- Consider 0.075% capsaicin ointment four times daily as adjunct to guideline-directed antiemetics
- Only after standard prophylaxis (NK1 antagonist + 5-HT3 antagonist + dexamethasone) has been optimized
For other causes of nausea/vomiting:
- Not recommended - use evidence-based antiemetics per indication (metoclopramide, ondansetron, haloperidol, olanzapine) 8, 5, 6
Bottom Line
Capsaicin has guideline-level support only for CHS 1 and emerging trial evidence for delayed CINV 4. The quality of evidence remains limited by small sample sizes and methodological concerns 10, 3. It should be positioned as an adjunctive therapy rather than replacing standard antiemetic regimens that have stronger evidence for improving morbidity and quality of life.